Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses may pose enormous challenges to our healthcare system. We evaluated the performance of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-time PCR Kit (PowerChek; Kogene Biotech, Seoul, Korea) in comparison with the BioFire Respiratory Panels 2 and 2.1 (RP2 and RP2.1; bioMérieux, Marcy l'Étoile, France), using 147 nasopharyngeal swabs. The limit of detection (LOD) of the PowerChek assay was determined using SARS-CoV-2, influenza A, and B RNA standards. The LOD values of the PowerChek assay for SARS-CoV-2 and influenza A and B were 1.12, 1.24, and 0.61 copies/μL, respectively. The positive and negative percent agreements of the PowerChek assay compared with RP2 and RP2.1 were 97.5% (39/40) and 100% (107/107) for SARS-CoV-2; 100% (39/39) and 100% (108/108) for influenza A; and 100% (35/35) and 100% (112/112) for influenza B, respectively. The performance of the PowerChek assay was comparable to that of RP2 and RP2.1 for detecting SARS-CoV-2 and influenza A and B, suggesting its use in diagnosing SARS-CoV-2 and influenza infections.

中文翻译：

---

PowerChek SARS-CoV-2、甲型和乙型流感多重实时 PCR 试剂盒与 BioFire 呼吸面板的性能评估。

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 和流感病毒可能对我们的医疗保健系统构成巨大挑战。我们与 BioFire Respiratory Panels 2 和 2.1（RP2 和 RP2.1； bioMérieux，Marcy l'Étoile，法国），使用 147 个鼻咽拭子。PowerChek 检测的检测限 (LOD) 是使用 SARS-CoV-2、流感 A 和 B RNA 标准确定的。PowerChek 检测对 SARS-CoV-2 和甲型和乙型流感病毒的 LOD 值分别为 1.12、1.24 和 0.61 拷贝/μL。SARS-CoV-2 与 RP2 和 RP2.1 相比，PowerChek 检测的阳性和阴性百分比一致性分别为 97.5% (39/40) 和 100% (107/107)；100% (39/39) 和 100% (108/108) 用于甲型流感；B 型流感分别为 100% (35/35) 和 100% (112/112)。PowerChek 检测的性能与 RP2 和 RP2.1 在检测 SARS-CoV-2 和甲型和乙型流感方面的性能相当，表明它可用于诊断 SARS-CoV-2 和流感感染。